These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36971576)

  • 21. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
    Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naldemedine: A Review in Opioid-Induced Constipation.
    Blair HA
    Drugs; 2019 Jul; 79(11):1241-1247. PubMed ID: 31267482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors affecting the effect of naldemedine for opioid-induced constipation: a single-institution, retrospective analysis.
    Kanbayashi Y; Amaya F; Ueno H; Tabuchi Y; Ishikawa T; Takayama K; Taguchi T
    Pharmazie; 2021 Apr; 76(4):175-178. PubMed ID: 33849704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peripherally-active mu-opioid receptor antagonists for constipation in critically ill patients receiving opioids: A case-series and a systematic review and meta-analysis of the literature.
    Umbrello M; Venco R; Palandri C; Racagni M; Muttini S
    Neurogastroenterol Motil; 2023 Dec; 35(12):e14694. PubMed ID: 37869768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naldemedine versus placebo in opioid-induced constipation: a meta-analysis.
    Wobbe B; Gerner M; Köhne CH
    BMJ Support Palliat Care; 2024 Jan; 13(e3):e578-e584. PubMed ID: 36517204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine.
    Fukumura K; Yamada T; Yokota T; Kawasaki A
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):162-174. PubMed ID: 30977959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of naldemedine is associated with reduced incidence of hyperactive delirium in cancer patients with opioid-induced constipation: A nationwide retrospective cohort study in Japan.
    Abe H; Sumitani M; Matsui H; Inoue R; Fushimi K; Uchida K; Yasunaga H
    Pharmacotherapy; 2022 Mar; 42(3):241-249. PubMed ID: 34967450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
    Song X; Wang D; Qu X; Dong N; Teng S
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naldemedine for the Use of Management of Opioid Induced Constipation.
    Urits I; Patel A; Kiernan HC; Clay CJ; Monteferrante N; Jung JW; Berger AA; Kassem H; Hasoon J; Kaye AD; Kaye AM; Viswanath O
    Psychopharmacol Bull; 2020 Jul; 50(3):97-118. PubMed ID: 32733114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancer pain.
    Liu JJ; Quinton SE; Brenner DM
    Pain Manag; 2020 Sep; 10(5):301-306. PubMed ID: 32552565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Naldemedine-laxative combination: retrospective inpatient study.
    Takemura M; Niki K; Miyaguchi S; Ueda M
    BMJ Support Palliat Care; 2024 Jan; 13(e3):e816-e819. PubMed ID: 35750467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid withdrawal syndrome developing after long-term administration of naldemedine.
    Ishida M; Uchida N; Yabuno A; Hasegawa K; Mizunuma N; Takahashi T; Onishi H
    Palliat Support Care; 2022 Dec; 20(6):897-899. PubMed ID: 35543119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Management of Opioid-Induced Constipation in Cancer and Advanced Illness: A Meta-Analysis.
    Jesuyajolu DA; Abubakar AK; Kowe T; Ogunlade S; Abioye AI; Tangeman J; Latuga N; Omotayo MO
    J Pain Symptom Manage; 2024 Apr; 67(4):e285-e297. PubMed ID: 38092261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Retrospective Observational Study of Factors Affecting the Efficacy of Concurrent Prescription of Naldemedine for Opioid-Induced Constipation Caused by Oxycodone Tablets.
    Yamada M; Jimaru Y; Torii S; Mitsuba N; Takahashi K
    Biol Pharm Bull; 2023; 46(12):1826-1831. PubMed ID: 38044102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Naldemedine for Patients with Cancer with Opioid-Induced Constipation in Clinical Practice: A Real-World Retrospective Study.
    Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Minato K; Obayashi K
    J Clin Med; 2022 May; 11(9):. PubMed ID: 35566798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting.
    Sato J; Tanaka R; Ishikawa H; Suzuki T; Shino M
    Support Care Cancer; 2020 Mar; 28(3):1083-1088. PubMed ID: 31183560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naldemedine (Symproic) for opioid-induced constipation.
    Med Lett Drugs Ther; 2017 Dec; 59(1535):196-198. PubMed ID: 29186083
    [No Abstract]   [Full Text] [Related]  

  • 38. Naldemedine effective in treating opioid-induced constipation.
    Brower V
    Lancet Oncol; 2017 Jun; 18(6):e306. PubMed ID: 28483411
    [No Abstract]   [Full Text] [Related]  

  • 39. Analysis of Predictive Factors for Diarrhea after the Administration of Naldemedine.
    Hashizume J; Shiojiri K; Ryu E; Kawauchi Y; Hasegawa K; Ezaki N; Yamashita H; Ishii K; Harasawa H; Nakamura T; Sasaki H; Kodama Y
    Biol Pharm Bull; 2021; 44(8):1081-1087. PubMed ID: 34334493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy Survey of Naldemedine in the Poor-performance Status Group].
    Kato S; Saito Y; Onoda H; Kumai M; Imai S; Tsuruga K; Takekuma Y; Sugawara M
    Yakugaku Zasshi; 2022; 142(7):755-760. PubMed ID: 35781505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.